Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays
FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024.
- Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
- Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
- The Alamar products represent a significant advancement in Alzheimer's Disease research, says Dr. Henrik Zetterberg.
- This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.